Filing Flows › Prime Medicine (PRME) › Q4 2025
Prime Medicine (PRME) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 3, 2026
Prime Medicine (PRME) reported revenue of $838K for the fourth quarter 2025 (Q4 2025), -62% from a year earlier and -32% from the quarter before.
Prime Medicine, Q4 2025: revenue $838K (-62% year over year), net loss $46.1M, operating cash flow −$37.3M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $838K | -32% | -62% |
| Operating profit | −$48.6M | — | — |
| Net earnings | −$46.1M | — | — |
| Operating cash flow | −$37.3M | — | -329% |
What changed
Revenue was $838K in Q4 2025, down 62% year over year and down 32% from the previous quarter.
Operating costs exceeded revenue by $48.6M, an operating margin of -5800.5%. Total costs grew 7% against a revenue fall of 62%. The fastest-growing cost line was General & admin (+20%). The quarter ended with a net loss of $46.1M, narrower than the previous quarter's $50.6M loss.
Operating cash flow was −$37.3M. Non-cash charges added back $1.9M of depreciation and amortization and $4.5M of share-based compensation. Working capital and other items added $2.4M. Capital expenditures of $290K exceeded it, leaving free cash flow of −$37.5M.
Questions
What was Prime Medicine's revenue in the fourth quarter 2025?
Prime Medicine (PRME) reported revenue of $838K for the fourth quarter 2025 (Q4 2025), -62% from a year earlier and -32% from the quarter before.
Source: Prime Medicine 10-K on SEC EDGAR.